Santen Pharmaceutical : Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System
September 30, 2021 at 03:02 am
Share
September 30, 2021
Notice on the Completion of Disposal of Treasury Shares for
the Post-delivery Type Performance-Linked Stock Remuneration System
Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereinafter, the "Company") announced that the disposal of treasury shares (hereinafter, the "disposal") related to the Post-delivery Type Performance-linked stock remuneration system was completed on September 30, 2021 based on the Board of Directors resolution of September 1, 2021, details of which are provided below. (Please see Santen's release on "Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System" dated September 1, 2021 for more details)
Details
Outline of the disposal
(1)
Type and number of shares
37,136 common shares of the Company's common stock
10 Corporate officers (excludes retired and resigned corporate
shares to be disposed of
officers ): 18,247 shares
3 retired and resigned Corporate Officers: 3,305 shares
(5)
Disposal date
September 30, 2021
Contact:
Kaori Itagaki
General Manager, IR Group
E-mail:ir@santen.comTel: +81-6-7664-8621
About Santen
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.
Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.
With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen's website (www.santen.com).
Attachments
Original document
Permalink
Disclaimer
Santen Pharmaceutical Co. Ltd. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 07:01:02 UTC.
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
Santen Pharmaceutical : Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System